You are here

JNJ

J&J says offered $2.1 billion for LifeScan diabetes unit

J&J says offered $2.1 billion for LifeScan diabetes unit

Yahoo/Reuters

Flag link:

J&J’s blockbuster hopeful erdafitinib gets ‘breakthrough’ moniker

J&J’s blockbuster hopeful erdafitinib gets ‘breakthrough’ moniker

Endpoints

breakthrough therapies

metastatic urothelial cancer

Flag link:

Forget Remicade -- Here's How Johnson & Johnson Plans to Grow

Forget Remicade -- Here's How Johnson & Johnson Plans to Grow

Motley Fool

Flag link:

Johnson & Johnson’s Ethicon loses $35m pelvic mesh lawsuit

Johnson & Johnson’s Ethicon loses $35m pelvic mesh lawsuit

Mass Device

Flag link:

Judge orders 1,200 Xarelto liability cases to be prepped for trials

Judge orders 1,200 Xarelto liability cases to be prepped for trials

Fierce Pharma

Flag link:

Five Events That Disrupted the Diabetes Market

Five Events That Disrupted the Diabetes Market

Medical Devices and Diagnostics Industry

blood glucose monitoring

artificial pancreas

FreeStyle Libre Flash

Flag link:

U.S. judge says opioid settlement roadblocks may prompt trials

U.S. judge says opioid settlement roadblocks may prompt trials

Reuters

Endo International

Teva Pharmaceutical

Flag link:

Senator questions big pharma buyback strategy

Senator questions big pharma buyback strategy

Biopharma Dive

share repurchase

Flag link:

Johnson & Johnson Advances in Robotics Surgery with Orthotaxy

Johnson & Johnson Advances in Robotics Surgery with Orthotaxy

Market Realist

robotic surgery

Flag link:

J&J collaborates with Aldeyra on new drugs for systemic inflammatory diseases

J&J collaborates with Aldeyra on new drugs for systemic inflammatory diseases

Endpoints

Aldeyra Therapeutics

inflammatory disease

Flag link:

3 Big Drugmakers Boosting Huge R&D Budgets

3 Big Drugmakers Boosting Huge R&D Budgets

Motley Fool

Bristol-Myers Squibb

Flag link:

Can Johnson & Johnson Replace Remicade for $100 Million Upfront?

Can Johnson & Johnson Replace Remicade for $100 Million Upfront?

Motley Fool

inflammatory bowel disease

Flag link:

J&J Acquisition Could Give Stryker a Run for Its Money in Robotics

J&J Acquisition Could Give Stryker a Run for Its Money in Robotics

Medical Devices and Diagnostics Industry

Flag link:

J&J Is Exploring a Sale of Its $2 Billion Sterilization Division

J&J Is Exploring a Sale of Its $2 Billion Sterilization Division

Bloomberg

Flag link:

Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

Fierce Pharma

Flag link:

A Possible Financial Boost Awaits Thousands Of Out-Of-State Plaintiffs In Risperdal suit

A Possible Financial Boost Awaits Thousands Of Out-Of-State Plaintiffs In Risperdal suit

Forbes

Flag link:

Johnson & Johnson’s stay-out-of-jail marketing for schizophrenia blockbuster Invega Sustenna raises eyebrows

Johnson & Johnson’s stay-out-of-jail marketing for schizophrenia blockbuster Invega Sustenna raises eyebrows

Fierce Pharma

Invega Sustenna

Flag link:

J&J gets first-of-its-kind prostate cancer approval

J&J gets first-of-its-kind prostate cancer approval

Biopharma Dive

prostate cancer

Flag link:

J&J strikes potential $1B JAK inhibitor deal with Theravance

J&J strikes potential $1B JAK inhibitor deal with Theravance

Biopharma Dive

drug development

Crohn's Disease

ulcerative colitis

Flag link:

Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J

Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J

JD Supra

Flag link:

Pages